Author

Diane R. Mould 1

1 Projections Research Inc,Phoenixville,United States

ANTIBODIES TO INFLIXIMAB, BODY WEIGHT AND LOW SERUM ALBUMIN LEVELS INCREASE CLEARANCE OF INFLIXIMAB, A POPULATION PHARMACOKINETIC STUDY IN 332 IBD PATIENTS

Johannan Frank Brandse, Diane R. Mould, Yaël Ashruf, Oscar Smeekes, Gijs R. van den Brink, Geert R. D'Haens

BODY WEIGHT AND RAPID CLEARANCE DETERMINE EARLY FORMATION OF ANTI-DRUG ANTIBODIES AGAINST INFLIXIMAB.

Walter Reinisch, Alexander Eser, Stefan Schreiber, Hyuk Chan Kwon, Diane R. Mould

INFORMATION NECESSARY TO PREDICT INDIVIDUAL INFLIXIMAB (IFX) PHARMACOKINETICS (PK) IN PATIENTS WITH IBD

Alexander Eser, Harald Vogelsang, Gottfried Novacek, Sieglinde Reinisch, Christian Primas, Sonja Brehovsky, Diane R. Mould, Walter Reinisch

POPULATION PHARMACOKINETIC EVALUATION OF INFLIXIMAB REVEALS PATIENT FACTORS THAT INCREASE INFLIXIMAB CLEARANCE AND SHORTEN HALF-LIFE IN INFLAMMATORY BOWEL DISEASE PATIENTS

Iris Dotan, Henit Yanai, Stuart Becker, Sigal Fishman, Lior Yahav, Merav Ben Yehoyada, Diane R. Mould

THE APPROPRIATENESS OF TESTING AND INTERPRETATION OF ANTI-TNF DRUG AND ANTIBODY CONCENTRATIONS: WHEN SHOULD THEY BE ORDERED, AND WHAT TO DO WITH THE RESULTS?

Gil Y. Melmed, Peter Irving, Gilaad G. Kaplan, Brian Bressler, Jennifer Jones, Patricia Kozuch, Miles P. Sparrow, Fernando Velayos, Leonard Baidoo, Adam Cheifetz, Shane Devlin, Laura Raffals, Niels Casteele, Diane R. Mould, William Sandborn, Corey A Siegel

Item 1 - 5 / 5
1